Clear answers,
without the jargon.

Transcranial magnetic stimulation is a noninvasive treatment that uses magnetic pulses to stimulate targeted brain circuits. Candidacy depends on diagnosis, treatment history, safety factors, device/protocol, and other clinical considerations.

Spravato® is intranasal esketamine. It is administered in a certified healthcare setting under supervision and requires post-dose monitoring under its REMS program.

No. Ketamine and esketamine are related but distinct. Spravato® has FDA-approved psychiatric indications and a REMS program. Psychiatric ketamine treatment is off-label.

Yes. CA Cortex begins with a psychiatric assessment before recommending TMS, esketamine, ketamine, or another treatment approach.

Coverage varies by treatment, diagnosis, payer, prior treatment history, authorization criteria, and site of care. Each case should be verified individually.

The model is designed primarily for specialty practices such as pain management and neurology that routinely care for patients with significant psychiatric comorbidity and want a more integrated pathway.

Potentially, but only when staffing, training, device requirements, supervision, payer rules, and the final legal structure permit it. Those details are reviewed before launch.

No. A 50/50 physician arrangement may be one concept in some circumstances, but ownership and contracts must be structured case by case with qualified healthcare counsel and applicable payer requirements.

Physician clinical judgment must remain with appropriately licensed physicians. The partnership model is designed around physician-led evaluation, treatment selection, mapping, and oversight.

We model eligible patient volume, payer mix, collections, authorization rates, staffing, room cost, equipment terms, billing expense, and physician services before deciding whether a program is viable.